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Abstract: Mutations of RAS oncogenes are responsible for about 30% of all human cancer types,
including pancreatic, lung, and colorectal cancers. While KRAS1 is a pseudogene, mutation of
KRAS2 (commonly known as KRAS oncogene) is directly or indirectly associated with human
cancers. Among the RAS family, KRAS is the most abundant oncogene related to uncontrolled cellular
proliferation to generate solid tumors in many types of cancer such as pancreatic carcinoma (over
80%), colon carcinoma (40–50%), lung carcinoma (30–50%), and other types of cancer. Once described
as ‘undruggable’, RAS proteins have become ‘druggable’, at least to a certain extent, due to the
continuous efforts made during the past four decades. In this account, we discuss the chemistry
and biology (wherever available) of the small-molecule inhibitors (synthetic, semi-synthetic, and
natural) of KRAS proteins that were published in the past decades. Commercial drugs, as well as
investigational molecules from preliminary stages to clinical trials, are categorized and discussed in
this study. In summary, this study presents an in-depth discussion of RAS proteins, classifies the RAS
superfamily, and describes the molecular mechanism of small-molecule RAS inhibitors
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1. Introduction
The human body is one of the most complicated biological systems, where hundreds
to thousands of biochemical, biophysical, and physicochemical transformations occur at
every moment. Most of these biotransformations are catalyzed by enzymes or associated
with enzymes/proteins. Several studies found that a set of genes responsible for cancer
pathogenesis originated from the transforming activity of the Harvey and Kirsten murine
sarcoma retroviruses and referred to them as RAS (rat sarcoma virus) in the early 1980s [1].
The initial study of RAS identified them as viral genes. They were then attributed to
the rodent genomes and thought to be the cause of the oncogenic properties of tumor
viruses [2]. Later, in 1982, the first human RAS genes and RAS proteins were identified,
and their mutational activation was observed in human cancer cell lines. Three of the
four deadliest cancers in the US, lung, colon, and pancreatic cancer, show RAS mutations’
prevalence, which also extends to other human cancers [3].
The human RAS protein family now includes more than 150 proteins encoded by genes:
HRAS, KRAS, and NRAS. It is known that 86% of mutations in the RAS protein, which
constitutes mutated RAS proteins in cancer, come from the one most closely related to the
KRAS genes. KRAS genes are responsible for several types of cancer, and 90% of pancreatic
cancer cases are directly attributable to KRAS mutations [2,4]. Along with the specific
types of cancers, RAS proteins are also responsible for other diseases such as RASopathy,
Capillary Malformations, and Psychiatric and Neurodevelopmental Disorders [5].
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Studies found that aberrant RAS mutation is associated with hyperproliferation developmental disorder and specific mutations in codons 12, 13, and 61. GTP-binding occurs
within the particular site and activates RAS signaling. Importantly, all RAS isoforms share
sequence identity in all the regions responsible for GDP/GTP binding, GTPase activity,
and effector interactions, which suggests functional redundancy. Several synthetic and
natural small molecules were evaluated in RAS-dependent cell lines, and mechanistic
investigations were carried out in many instances. Despite unceasing progress, many miles
remain in the development of drugs with higher potency and lower toxicity.
2. Classification of RAS Protein Superfamily
The RAS protein superfamily comprises small guanosine triphosphatase chemicals
(GTPases) that act as molecular on/off switches for numerous cellular activities in response
to extracellular signals. The RAS family of proteins functions as a set of signaling nodes
triggered by various extracellular stimuli. They also control intracellular signaling. Such
signaling eventually regulates gene transcription and influences fundamental processes
such as cell growth and differentiation [6–10]. Based on their genetic sequences and
biological activities, we found five distinct groups of the RAS superfamily: RAS, Rho,
Arf/Sar, Ran, and Rab (Figure 1) [6,8].

Figure 1. Classification of the RAS superfamily [6,11].

2.1. RAS Subfamily
There are 36 proteins, collectively called RAS oncoproteins, that are the original
members of the RAS family. This subfamily has been the topic of much research. The
RAS family of human oncogenic members has been intensively investigated, and they
modulate cell proliferation, differentiation, morphology, and apoptosis in general. In 1993,
the protein kinase Raf was studied and recognized as a RAS effector. RAS is activated
when it binds to the Raf serine/threonine kinase. Activated RAS facilitates translocation
to the plasma membrane, where additional phosphorylation events enhance Raf kinase
activation in its entirety [1,9]. The RAS proteins HRAS, KRAS, and NRAS (H, K, NRAS)
are RAS oncoproteins that cause human cancers. The transfusion-based assay can isolate
them [10,12,13] from human tumor cells. These three isoforms are most prevalent in human
cancers. In addition, the same proteins have recently been linked to central nervous system
neuronal plasticity. Among the signaling molecules that are indirectly linked to various
cell surface receptors, RAS proteins play a vital role in responding to a wide range of
extracellular observations [14].
Most RAS subfamily proteins are primarily found in the plasma membrane area.
Therefore, C-terminal prenylation contributes to membrane localization. There is a common
Caax (a = aliphatic, x = terminal amino acid) pattern that most prenylation signals follow.
This pattern guides cysteine farnesylation (except when x = L or F, which leads to the
geranylgeranylation process, commonly seen on RRAS and some other RAP proteins).
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During the prenylation reaction, proteolysis of the three C-terminal residues (aax) occurs,
and methylation of the lipid-modified cysteine is completed [15,16]. RAS subfamily proteins
such as the Rap, RRAS, Ral, and Rheb proteins help control the signaling network. RRAS
participate in various complex activities such as angiogenesis, regeneration, vascular
homeostasis, cell adhesion, and neuronal axon guidance, but their mutation causes invasive
cancers [17,18]. Mitogenic stimuli activate Rap proteins, which operate as the controllers
of integrin-mediated cell adhesion as well as cell spreading [19]. Ral proteins’ functions
include mitogenic responses, protein trafficking, differentiation, and cytoskeleton dynamics.
Investigations found that the two Ral proteins play independent and complementary roles
in cell transformation [20]. RalA promotes anchorage-independent cell proliferation, but
RalB is required to survive against tumor cells [21]. The Rheb protein is largely involved in
regulating the cell cycle [22]. Some early studies found that the Rheb protein also performs
two additional functions: blocking of MAPK or mitogen-activated protein kinase signaling;
inhibiting the RAS-mediated transformation of cultured fibroblasts [23].
2.2. Rho Subfamily
The RAS homolog (Rho) subfamily is closely related to the RAS subgroup. The Rho
family mainly operates in signaling networks that subsequently regulate three processes:
actin, cell cycle progression, and gene expression [24]. In addition, Rho GTPases are critical
cytoskeletal regulators that influence various cellular activities, including cell polarity,
migration, vesicle trafficking, and cytokinesis. Rho GTPases have been investigated extensively in several mammalian cell types, with dominant-negative and constitutively active
mutants primarily being employed [25]. Rho GTPases have also been identified as crucial
regulators of cell polarity. They act as molecular regulators between two states: active
GTP–bound and inactive GDP–bound [26]. In addition, many studies have implicated
members of the Rho family in hematopoiesis. Multiple human hematologic disorders,
including neutrophil dysfunction, leukemia, and Fanconi anemia, have been associated
with the deregulation of Rho GTPase family members, increasing the possibility that Rho
GTPases and their downstream signaling pathways could be helpful therapeutically [27].
RAC proteins have emerged as essential mediators of Wnt signals, mainly in noncanonical and canonical pathways leading to β-catenin-dependent transcription. Wnt-induced
signals appear to promote morphological and transcriptional alterations that affect cell
behavior spatially and temporally [28].
To understand the Rho family’s evolutionary history, there have been investigations
on over 20 species, including major eukaryotic clades, unicellular organisms, various mammals, platypus, opossum, and so on. Studies include the reconstruction of the ontogeny
and chronology of the development of distinct Rho subfamilies. There are eight subfamilies
among the 20 mammalian Rho members. The Rac, Rho, and Cdc42 subgroups have been
extensively studied among the eight Rho subfamilies [29]. Most likely, 20 canonical Rho
members (Rho GTPases) are regulated by four guanine nucleotide dissociation inhibitors
(GDIs), 85 guanine nucleotide exchange factors (GEFs), and 66 GTPase-activating proteins
(GAPs) [30].
2.3. Rab Subfamily
Rab proteins are small GTP-binding proteins, first characterized as RAS-like genes
exhibited in rat brains [31], that comprise the biggest subfamily of the RAS protein superfamily. The yeast Saccharomyces cerevisiae expresses eleven Rab (Yptp/Sec4p) proteins.
However, based on the expressed-sequence tags (ESTs) and the sequenced human genome,
there could be as many as 63 Rab (Yptp/Sec4p) proteins in humans. Rab proteins act as
membrane-associated molecular switches between different organelles to regulate vesicular
trafficking pathways. The Rab subfamily promotes vesicular or tubular carriers’ budding
in further steps such as the donor-compartment, transport-to-acceptor, vesicle-fusion, and
load-release steps [32,33].
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Rab GTPases are connected in reverse to membranes by hydrophobic geranylgeranyl
groups attached to one or (usually) two carboxy-terminal Cys residues, which is essential
for controlling the membrane traffic. Rab proteins are regulated by their ability to act as
molecular switches, similar to the other GTPases, that wiggle between GTP- and GDPbound conformations.
Each transport step starts with the binding of activated Rab proteins to soluble factors
that function as ‘effectors’, allowing the transduction of the Rab GTPase signal. Several
RAB effectors have been identified. Rab effectors’ structural heterogeneity suggests a
collection of highly specialized molecules that function exclusively on specific organelles
and transport systems [34]. Rab pathway dysfunction has been linked to diseases such as
immunodeficiencies, cancer, and neurological disorders.
2.4. Ran Subfamily
Ran is a member of the RAS superfamily, which is the most abundant small GTPbinding protein. Ran proteins are localized mainly within the nucleus [35]. These proteins
regulate the nuclear import/export of materials. In addition, DNA replication, mitotic
spindle assembly, and nuclear envelope assembly [36] are also controlled by these proteins.
Although the RAN protein is related to the Rab subfamily, it has characteristics that set it
apart. Ran function depends on a spatially bounded form of the GTP of Ran, unlike other
small GTPases. Nuclear trafficking studies identified the switching behavior of Ran. It was
found that Ran functions as a molecular switch and controls nuclear transport receptor–
cargo complexes [37,38]. The assembly and disassembly of nuclear transport receptors
depend on the guanine-nucleotide-bound state of Ran.
2.5. Arf Subfamily
Similar to the Rab protein family, the Arf family of proteins is another diverse group of
proteins that are involved in vesicle trafficking [6]. This subfamily’s first members function
as ADP ribosylation factors, and they were named accordingly. Arf proteins play a role in
vesicle formation and structure, as well as intracellular vesicular transport, endocytosis,
and exocytosis [39–41]. The Arf family consists of 30 genes, divided into four groups:
1.
2.
3.
4.

The Arfs
The Arf-like (Arls) proteins
The Secretion-associated RAS-related (SARs) proteins
The single Tripartite protein 23, also known as TRIM23.

ARF GTPases constitute a significant family of eukaryote-specific GTPases. They
regulate membrane traffic, actin dynamics, tubulin assembly, and cilia-related functions.
Every Arf isoform has several biochemical effects that can be put together to elicit a specific
cellular behavior or event. This phenomenon helps researchers assess the pathway’s
potential as a target in disorders such as cancer [42,43].
2.6. KRAS, HRAS, and NRAS
Three RAS proteins, HRAS, KRAS, and NRAS, are expressed in all mammal cells and,
thus, are closely related. Hence, the aberrant mutation of these three proteins can contribute
to the development of oncogenesis, which is often attributed to a unique mutation, and this
typically occurs at codons 12, 13, or 61. Investigations have found RAS mutations in 30% of
human cancers. Though isoforms have a lot in common, each isoform prefers to couple to
specific cancer types. Therefore, there has been much analysis of the mutational spectra of
RAS isoforms. One such study shows that factors other than the differences in mutagen
exposure exist that contribute to the heterogeneity observed across a single isoform.
2.6.1. KRAS
The KRAS gene is found to be mutated in various types of tumors, such as pancreatic carcinoma (over 80%), colon carcinoma (40–50%), lung carcinoma (30–50%), and
others [11,43–46]. The KRAS isoform causes about 85% of RAS mutations. Human KRAS
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oncogenes are activated in two ways: when oncogene copies increase abruptly or when
the tumor suppressor gene p53 is lost abnormally. When oncogenic KRAS is activated, a
mutant KRAS protein remains actively GTP-bound for an extended period. KRAS cycles
between two states: an inactive bound GDP state, and an active GTP-bound state. However,
only the GTP-bound state of KRAS is necessary for Raf-kinases, PI3K, and RalGDS to bind
and consequently activate their effector proteins [47].
2.6.2. HRAS
HRAS mutation comprises 12% of overall RAS mutations. HRAS is one of three
human RAS proteins that encode the GTPase HRAS protein. HRAS mutations are found
in bladder urothelial carcinoma, breast-invasive ductal carcinoma, lung adenocarcinoma,
prostate adenocarcinoma, and colon adenocarcinoma, with these having the most significant prevalence of alterations. However, HRAS mutations are also prevalent in the bladder
(4.5%), thyroid (3.2%), and head-and-neck carcinoma (5.1%) [48].
2.6.3. NRAS
NRAS is the minor cancer-causing mutant among the three human RAS proteins,
and approximately 2.3% of overall RAS mutations occur because of the NRAS mutant.
Oncogenic mutations of NRAS genes in human tumors follow a different distribution
pattern, with the highest rates of mutation found at codon Q61 (about 60% of total NRAS
mutations) and lower percentages detected at G12 (24.4%) and G13 (12.7%) [49]. Moreover,
it was found that NRAS mutations are prominent in hematopoietic and skin (melanocyte)
malignancies and myelomas [1].
3. RAS and Cancers
3.1. Pancreatic Cancer
Most cases of pancreatic cancer have mutations in the KRAS gene at the time of
diagnosis (>80% of cases). It was found that 90% of pancreatic cancers are developed in
the exocrine compartment of the pancreas and cause pancreatic ductal adenocarcinoma
(PDAC). Codon 12 is accountable for 98% of PDAC mutations. Research found that codon
G12D (51%) is the most aggressive PDAC subtype, followed by G12V (30%), G12A/C/S (2%
each), and G12L/F (<1%) (Figure 2) [50]. KRAS plays a vital role in developing PDAC-type
pancreatic cancer [51]. The progression of PDAC occurs due to the loss of the tumorsuppressor gene cyclin-dependent kinase inhibitor 2A (CDKN2A) [52]. Although KRAS
mutations are undruggable and no anti-KRAS therapies exist for them, some inhibitors
show effects against cancers. Inhibition of the RAF-MEK-ERK protein kinase pathway is
one of the most potent factors that work against KRAS mutation. This pathway has an
important role in the progression of PDAC [53]. It is also reported that iExosomes inhibit
PDAC in mice by delivering RNAi. However, exosomes have therapeutic potential to
control KRAS-dependent pancreatic cancer [54,55]. Additionally, the KRAS mutation can be
inhibited by using a slow-released biodegradable polymer matrix. This process works by
delivering siRNA as an extended-release drug to mutated KRAS [56]. Another method for
suppressing the KRAS mutation is anti-RAS vaccination. These vaccines contain different
mutated genes that work against KRAS mutations [57,58].
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Figure 2. Frequency of KRAS, HRAS, and NRAS in different types of cancer [2,50,59,60].

3.2. Lung Cancer
Lung cancer ranks as the primary cause of cancer-related death among men and
women worldwide. Researchers first identified activation of KRAS mutations to cause lung
cancers. KRAS mutations are responsible for the majority of lung adenocarcinoma (LADC)
and are also seen in non-small-cell lung cancer (NSCLC). KRAS mutations cause 30% of
lung carcinoma cases. Significantly, 90% of RAS mutations in LDAC are KRAS mutations,
and this figure is around 97% in NSCLC [61,62]. Furthermore, the study suggests that
KRAS mutations are more frequent in African American patients than in Asian patients
(Figure 2) [63,64]. An investigation of restricted NSCLC tumors, in particular, indicated
that KRAS mutations are more common in younger patients, especially young women [65].
Researchers determined that smoking history is essential in the regulation of KRAS
mutation in lung cancer. Studies found that a significant amount of lung cancer patients are
cigarette smokers, and KRAS mutation is also frequent in adenocarcinomas. Furthermore,
it was also identified that 30% of current and former smokers exhibit lung adenocarcinoma.
However, KRAS mutation is also found in never-smokers, but the percentage of KRAS
mutations is higher in smokers [50,66].
3.3. Colorectal Cancer
Colorectal cancer (CRCs) is one of the principal causes of death in men and women in
the United States [67]. Multiple genetic alterations make colon carcinoma more fatal. About
50% of KRAS mutations are responsible for codon 13,14, and 64 in colon adenomas [68,69].
Nearly 40% of KRAS mutation occurs for G12D, G12V, and G13V that activate the MAPK
signaling pathway (Figure 2) [70]. Although extensive studies have been conducted to find
the therapeutics in CRC treatment, there is still no direct inhibitor of KRAS mutations [71].
More effective treatment and biomarkers are needed because a large percentage of colon
cancer is associated with the KRAS oncogenes.
3.4. Other Cancers
RAS mutations comprise a vast portion of cancer-causing diseases. RAS mutations
also occur in other cancers such as breast cancer, head-and-neck cancer, bladder tumors,
skin cancer, prostate cancer, etc. More attention is needed to identify the RAS inhibitors.
4. Small-Molecule RAS Inhibitors
Small molecules are drugs that impede the cellular pathway or molecules within the
pathway. Small-molecule drugs/inhibitors can enter the cell easily because of their low
molecular weight and balanced ADME properties. They can target the extracellular cell
surface receptor as well as intracellular proteins. After entering the cells, they inhibit other
molecules such as proteins or enzymes, which causes various types of disease. For example,
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gefitinib is a small-molecule anticancer drug used to treat non-small-cell lung cancer [72].
Gefitinib blocks the signaling pathway of epidermal-growth-factor receptors (EGRF), which
are responsible for cell proliferation, invasion, etc. RAS proteins contribute considerably to
many types of cancer. There is no more effective treatment for RAS mutations. In terms of
finding an effective means of treating undruggable RAS mutation, small-molecule drugs or
inhibitors can be an effective option for cancer treatment, inspired by robust investigation
and research.
4.1. Classification of Small-Molecule RAS Inhibitors Based on Their Structure
Nowadays, structure-based drug discovery is becoming an essential strategy for
treating various diseases, especially cancer. This strategy is now in vogue because of
its cost-effectiveness and faster results compared to traditional drug-discovery methods.
However, structural data provide the molecular mechanisms and fundamental functions
of a compound. Structural studies have provided hundreds of new targets, and when the
target is identified, it is essential to obtain accurate structural information.
This study classified and discussed small-molecule RAS inhibitors according to their
structure. We found that most of the RAS inhibitors are heterocyclic compounds. The
cyclic part (from the Greek “kyklos”, meaning “circle”) of “heterocycle” indicates that at
least one ring structure is present in such a compound, while the prefix hetero- (from the
Greek “heteros”, meaning “other” or “different”) refers to any atoms other than carbon
(heteroatoms) [73]. The most common heterocycles have four- or five-membered rings
containing nitrogen, oxygen, and a sulfur atom. These diverse heterocyclic compounds
have found applications as pharmacophores. These pharmacophores are often found
in synthetic and natural product drugs. Researchers and pharmaceutical companies are
interested in heterocyclic pharmacophores due to their fascinating medicinal properties.
We also found that the carbocyclic compound also has RAS-inhibitory properties. Thus,
studying the heterocyclic and carbocyclic RAS inhibitors might be an excellent resource for
finding potent small-molecule inhibitors for cancer treatment.
Based on the structure aza heterocyclic small-molecule RAS inhibitors with one nitrogen atom are shown in Table 1. After careful review, the mechanistic properties, cancer
type and major pharmacophores are also described.
Table 1. Aza heterocyclic small-molecule RAS inhibitors with one nitrogen atom.
Major
Pharmacophore(s)

Cancer Type

Targeted Enzyme
M/A

References

Indole, Triazolone,
Resorcinol

Lung
cancer/colorectal
cancer

Inhibits heat-shock
protein 90 (Hsp90)

[74]
[75]

Apatinib

Pyridine

Metastatic lung
cancer/breast
cancer/gastric
cancer

Inhibits vascular
endothelial growth
factor receptor-2
(VEGFR-2)

[76]

Oncrasin-1

Indole,
Chlorophenyl

Lung cancer

Inhibits
K-RAS/PKCι
pathway

[77]

Compound Name

Ganetespib

Structure
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Table 1. Cont.
Major
Pharmacophore(s)

Cancer Type

Targeted Enzyme
M/A

References

†

Indole, Azetidine,
Isoquinoline

Unknown

Inhibits KRASG12C
mutation

[78]

††

Piperidine,
Disulfide linkage

Unknown

Inhibits KRASG12C
mutation

[79]

GDC-0449
(Vismodegib)
combined
with miRNA

Pyridine,
Chlorobenzene,
Sulfonyl

Pancreatic cancer

Hedgehog (Hh)
inhibitor

[80]

Compound Name

Structure

† = N-(1-acryloylazet-id-in-3-yl)-2-(5-bromo-3-(5-methoxy-1,2,3,4-tetrahydroi-soquino-line-2-carbonyl)-1H-indol1-yl) acetamide; †† = 2-((4-((1-(2-(2,4-dichlorophenoxy) acetyl) piperidin-4-yl) amino)-4-oxobutyl) disulfaneyl)N,N-dimethylethan-1-aminium.

4.1.1. Ganetespib
The heat-shock protein 90 (Hsp90) is inhibited by ganetespib (Table 1) leading to the
degradation of many oncogenic proteins such as v-Raf murine sarcoma viral oncogene
homolog B, VEGF receptor, EGFR, Cyclin D1, and mutant p53 [74]. Acquaviva et al. [75]
found that ganetespib, a small-molecule inhibitor, suppresses human lung cancer in individualized therapy. Ganetespib showed a potent cytotoxic effect in both in vitro and
in vivo studies by inhibiting Hsp90. A set of twenty NSCLC cell lines with known KRAS
mutations, including the G12, G13, and Q61, variants, were targeted to identify the cytotoxic activity of ganetespib. Cell lines H727 and H441 showed IC50 values of 28 and
14 nmol/L against the KRASG12V mutant, respectively, which indicates that the smallmolecule inhibitor ganetespib is responsive to KRAS mutation. Additionally, ganetespib
and the PI3K/mTOR inhibitor BEZ235 showed potential effects in a A549 xenograft model.
Finally, a phase II clinical study specified 47% tumor shrinkage in the KRAS-harbored
mutation. In 2017, Cercek et al. [74] hypothesized that ganetespib might be an excellent
small-molecule inhibitor in colorectal cancer as KRASG12V is one of the main mutants
responsible for apoptosis, cell cycle control, and angiogenesis [81,82]. However, in a phase
II study with seventeen patients, significant antitumor activity was not shown with Ganetespib (200 mg/m2 ) treatment when administered intravenously. Interestingly, out of nine
patients (3 G12D, 4 G12V, 1 G12S, and 1 G12C), two patients, harboring G12V mutations
showed stable conditions.
4.1.2. Apatinib
Apatinib (Table 1) is a small-molecule tyrosine kinase inhibitor that significantly
works against metastatic breast cancer and gastric cancer by selectively inhibiting vascular
endothelial growth factor receptor-2 (VEGFR-2) [83,84]. In 2017, it was reported that the
dosing effect might vary the effectiveness of apatinib in different types of cancer [76]. Their
results for four advanced-stage (stage-IV) patients with KRAS mutation, aged 56–81 years,
who were diagnosed with metastatic lung adenocarcinoma indicated the potential positive
effect of apatinib. Among the four patients, three showed progression-free survival (PFS)
(1.5 months, 4.5 months, and 5.5 months) with a small dose. Only one patient was diagnosed
with manageable side effects (hoarseness and hemoptysis). Their implemented dosing
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amount (250 mg/d oral) was significantly lower than the previously studied large-scale
trial (500–850 mg/d), in which significant side effects were observed.
4.1.3. Oncrasin-1
A small-molecule compound, oncarsin-1 (Table 1) was identified by synthetic lethality
screening and was found to significantly suppress various lung cancers and might inhibit
the novel KRAS/PKCι pathway [77]. Although oncarcin-1 has a similar core structure to
indole-3-carbinol and lonidamine, an investigation found that it might follow different
anticancer mechanisms. This is because indole-3-carbinol [85] and lonidamine [85] have no
cytotoxic effect on T29, T29Kt1, T29Ht1, and H460 lung cancer cell lines, whereas oncarcin-1
shows anticancer effects in these cell lines. When T-29 (or T29Kt1) cells were treated with
10 µmol/L oncarsin-1 or H460 cells were treated with 1 µmol/L of oncarsin-1 (equivalent
to approximately IC80 doses) the apoptotic cell counts were 33.2%, and 47.2% respectively,
which indicated that oncarsin-1 has an effective apoptosis-induction mechanism. Additionally, to identify the KRAS-mutated cell death in H460 cells, orcarsin-1 treatment with
control siRNA-treated cells and KRAS siRNA-treated cells showed approximately 17% and
3% more apoptosis, respectively, when compared to treatment with DMSO + siRNA-treated
cells. In an in vivo study, oncarsin-1 treatment was compared to solvent-only treatment,
and the result showed 75.4% more tumor suppression with oncarsin-1 therapy [77].
4.1.4. N-(1-Acryloylazetidin-3-yl)-2-(5-bromo-3-(5-methoxy-1,2,3,4-tetrahydroisoquinoline2-carbonyl)-1H-indol-1-yl) Acetamide
Shin et al. found a series of novel KRASG12C inhibitors by exploring the chemotype
evolution (custom library synthesis accompanied by subsequent screening) and structurebased design strategies [78]. The newly synthesized compound (†) (Table 1) showed the
most potent and selective inhibition against KRASG12C mutants. The path of optimization
of this series of small molecules identifies the hidden surface groove bordered by the
side chain of Y96/H95/Q99 amino acids. Mechanistically, N-(1-acryloylazetidin-3-yl)-2-(5bromo-3-(5-methoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1H-indol-1-yl) acetamide
improves covalent interaction with specifically targeted proteins by means of submolecular
inhibition [78]. The first covalent irreversible interaction of KRASG12C was identified
by application of tethering, and allosteric binding of the compound in the P2 pocket
(near switch II region) resulted in the inhibition of RAS mutation [86]. Further study
found more successful results using electrophile screening. An irreversible interaction
was produced by means of chemotype evaluation of the anchor molecule (bait), which
helped to inhibit the KRASG12C mutation. Shin et al. reported an N-(1-acryloylazetidin-3yl)-2-(1H-indol-1-yl) acetamide that modifies KRASG12C by most actively hitting with the
indole bait and covalently binding with the switch II region. After checking the cytotoxic
effect on MIA PaCa-2 cell lines, the compound demonstrated an IC50 value of 0.638 µM.
Further investigation proved that adding methyl group in two positions of the indole group
increased the activity two-fold (IC50 = 0.299 µM) and two-fold (IC50 = 1.68 µM) in the
GTP 2 h exchange and cellular potency assays, respectively, in comparison to the previous
compound [78]. A recent report showed that Y96/H95/Q99 are mutated in cancer cells
under the influence of KRASG12C inhibitors [87].
4.1.5. 2-((4-((1-(2-(2,4-Dichlorophenoxy) acetyl) piperidin-4-yl) amino)-4-oxobutyl)
disulfaneyl)-N,N-dimethylethan-1-aminium
A newly developed small molecule (Table 1) exerts a therapeutic effect by inhibiting
KRASG12C mutants and binding to the allosteric pocket. This small-molecule inhibitor is
attached to the Cys of KRAS. It binds the allosteric binding site very close to the switching
II pocket (SW IIP), resulting in the disruption of GTP-state RAS conformation and the
impairment of Raf activity [79]. Although it is difficult to identify the specifically targeted allosteric binding site for a specific protein, cystine-dependent small molecules can
irreversibly bind with the allosteric binding site of the KRASG12C oncoprotein.
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A newly developed small molecule (Table 1) exerts a therapeutic effect by inhibiting
KRASG12C mutants and binding to the allosteric pocket. This small-molecule inhibitor is
4.1.6.toGDC-0449
(Vismodegib)
attached
the Cys of KRAS.
It binds the allosteric binding site very close to the switching
II pocket (SW IIP), resulting in the disruption of GTP-state RAS conformation and the
The combination therapy of a small-molecule hedgehog (Hh) inhibitor (GDC-0449)
impairment of Raf activity [79]. Although it is difficult to identify the specifically targeted
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1) (small
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inhibit
cancer
growth
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and in vivo [80]. Researchers found that
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binding
site ofboth
the KRAS

increasing the level of Hh signaling promotes cell proliferation by controlling EMT and PI3
in a kinase-dependent manner, which results in different types of cancer (pancreatic cancer,
The combination
therapy
of a small-molecule
hedgehog
(Hh)tumor,
inhibitor
(GDC-0449)
breast
cancer, colon
cancer,
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brain
and
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and
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4.1.6. GDC-0449 (Vismodegib)

mPEG-b-PCC-g-DC-g-TEPA copolymeric micelles encapsulate GDC-0449 and form a
complex with miR-let7b. The synergistic effect of these two inhibitors combined inhibited
4.2. Aza Heterocyclic Small-Molecule RAS Inhibitors with More Than One
pancreatic cancer in an in vitro and in vivo study [80].

Nitrogen Atom

In Table 2 Aza heterocyclic small-molecule RAS inhibitors with more than one nitrogen
atom are classified.
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classified.
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Table 2. Aza heterocyclic small-molecule RAS inhibitors with more than one nitrogen atom.

Targeted
Enzyme
References (M/A)

References

G12C
KRAS
[90]
inhibitor

[90]

G12C
KRAS
[91]
inhibitor

[91]

Piperazine, Fluorophenol, Pancreatic canKRASG12C inhibitor
Fluorophenol,
Fluocancer/Lung
Fluoropyrimidinone
cer/Lung cancer

G12C
KRAS
[92]
inhibitor

[92]

MRTX849
(Adagrasib)

Piperizine,
Chloronaphthalene,
Tetrahydropyrido[3,4d]pyrimidine

Pancreatic
cancer/Lung
cancer

KRASG12C
inhibitor

[93]

†††

Piperazine, Pyrazolopyrimidine

Pancreatic cancer

Inhibits
MAPK/RAF
signaling

[94]

Compound Name
Compound Name

Structure
Structure

Major

Cancer
TypeEnzyme
Targeted

Pharmacophore(s)
Major
Pharmacophore(s) Cancer Type

(M/A)

6-chloro-8-

ARS-1620
ARS-1620

6-chloro-8-fluoroquinazoUnknownUnknown
KRASG12C inhibitor
fluoroquinazoline,
line, Piperizine

Piperizine

Chlorophenol,

ARS-853
ARS-853

Chlorophenol, PiperaPiperazine,
zine,
Azetidine

UnknownUnknown
KRASG12C inhibitor

Azetidine

AMG
AMG510
510
(Lumakras or Sotora(Lumakras
or
sib)
Sotorasib)

Piperazine,

Pancreatic

ropyrimidinone

cancer
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Table 2. Cont.
Compound Name

BGB324
(Bemcentinib)

ABT-737

Structure

Major
Pharmacophore(s)

Targeted
Enzyme (M/A)

References

Axl kinase
inhibitor

[95]

Colon cancer

Represses
Bcl-2/Bcl-XL ,
resulting in
inhibition of the
RNAi of PAK4
and PAK1

[96]

[97]

Cancer Type

Cycloheptapyridazine,
Pyrrolidine,
Pancreatic cancer
Triazole

Chlorobiphenyl,
Piperazine

AZD6244
(Selumetinib)

Quinoline,
Imidazoquinoline

Colorectal cancer

Downregulation
of MEK1/2
pathway
inhibits KRAS
mutation

NVP-BEZ235
(Dactolisib)
in
Combination with
AZD6244
(Selumetinib)

Quinoline, Phenylpropanenitrile,
Imidazoquinolinone

Lung cancer

Dual pan
PI3K/MEK
inhibitor

[98]

R115777 (Zarnestra
or Tipifarnib)

Chlorophenyl,
Imidazole,
Quinolinone

Myeloma

Inhibits farnesyl
transferase
signaling

[99]

PPIN-1
PPIN-2

Biphenyl,
Imidazole, Npropyldiazepanone,
Tetrahydropyran

Unknown

PPI inhibitor

[100]

pan-RAS inhibitor
3144
(RAS-IN-3144)

Indole, Piperazine,
Trifluoromethoxyphenyl

Unknown

Downregulates
PI3K/AKT,
RAF/MEK/ERK
signaling

[101]

Deltarasin

Benzimidazole,
Piperidine

Pancreatic
cancer/Lung
cancer

Downregulates
RAS/RAF
signaling
pathway

[102]
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Table 2. Cont.
Compound Name

Structure

††††

Major
Pharmacophore(s)

Cancer Type

Targeted
Enzyme (M/A)

References

Fluoroquinoline,
Fluorophenol,
Piperazine,
Piperazinone

Unknown

KRASG12C
inhibitor

[103]

Unknown

Inhibits
KRASG12C
binding with
guaninebinding
site

[104]

SML-8-73-1
SML-8-73-1
Purine,
Tetrahydrofuran

SML-10-70-1
SML-10-70-1
††† = 1-(2-hydroxyethyl)-4-(2-methyl-3,5-diphenylpyrazolo[1,5-a] pyrimidin-7-yl) piperazin-1-ium. †††† = (2R,4aR)-3acryloyl-11-chloro-9-fluoro-10-(6-fluoro-2-hydroxycyclohexa-2,4-dien-1-yl)-2,6-dimethyl-2,3,4,4a-tetrahydro-1Hpyrazino [1’,2’:4,5] pyrazino[2,3-c] quinolin-5(6H)-one.

4.2.1. ARS-1620
The current study was successful in considering KRAS as a therapeutic target. The
new investigation might be a promising therapeutic approach for KRAS-dependent cancer
treatment. Article [90], which explored the KRASG12C S-IIP-binding site in a structure-based
design study, showed KRAS inhibition through the invention of a new covalent compound
(ARS-1620). ARS-1620 (Table 2) is the first orally bioavailable, potent, and selective smallmolecule KRASG12C inhibitor. Moreover, it also provides evidence of therapeutic inhibition
for both in vitro and in vivo studies. ARS-1620 treatment showed drastically different
results with 2D monolayer adherent and 3D ultra-low adherent suspension in in vitro
and in vivo studies [90]. Three-dimensional ULA spheroid culture showed a much more
effective result than 2D monolayer culture. This result suggested an inherent difference in
KRAS dependence in different types of culture cells.
4.2.2. ARS-853
Further studies were conducted to increase the potency of ARS 1620. An investigation
found that this small-molecule compound did not show any cellular response when bound
with non KRASG12C , even with 10-fold higher concentrations, but targeted the GDP-bound
protein ARS-853 (Table 2) and inactivated the signaling of KRASG12C with an IC50 value
of 1 µmol/L, indicating the selectivity of ARS-853 [91]. As a result, a more potent and
selective covalently bounded KRASG12C inhibitor was identified.
4.2.3. AMG 510 (Lumakras or Sotorasib)
To make the ARS-1620 more efficient and draggable, Canon et al. [92] developed a new
small-molecule inhibitor named AMG 510. This compound is superior to ARS-1620, and
they have minimal structural differences. The use of an irreversible strategy of the His95
groove, which is close to the cystine pocket AMG 510 (Table 2), produces robust inhibition
of the KRASG12C oncogene. It also downregulates the MAPK signaling pathway in both
pancreatic and lung cancer. However, it does not affect wild-type KRASG12C mutations,
which proves the specificity of AMG 510. After the consequent success, a further study
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was conducted to obtain a more efficacious result. Combinatorial therapy of AMG 510
with a MAPK inhibitor (carboplatin) created a more potent outcome than monotherapy.
These effective outcomes induced researchers to move forward. As a result, synergistic
effects were tested in a mice model, and 90% of mice showed complete tumor suppression.
Finally, a preliminary clinical study on the human model provided 50% tumor regression.
However, most of the success of these comprehensive studies relates only to the KRASG12C
oncogene, mostly found in lung cancer [105]. Only 2% of PDAC are responsible for the
KRASG12C oncogene [50]. Nevertheless, after reviewing this success, it was suggested that
the KRASG12D and KRASG12V mutations, responsible for approximately 80% of pancreatic
cancer, might be the primary targets for future studies [50].
4.2.4. MRTX849 (Adagrasib)
Another structurally modified small-molecule inhibitor, MRTX849 (Table 2), developed
by Jill Hallin et al. [93], was found to be a very potent, selective, and covalent KRASG12C
inhibitor in pancreatic and lung cancer, and is structurally and functionally close to the
AMG 510. This compound exerts effectiveness in combination therapy and has remarkable
potency when administered alone. Thus, a phase I clinical study was conducted with the
single agent in two patients with final-stage lung and colon carcinoma. The results showed
partial responses to these two critical types of cancer. However, the return of ERK signaling
and the lack of inhibition of mTOR-S6 signaling made the MRTX849 response short-lasting
and ineffective. The results from this study influence future expectations for pancreatic
cancer treatment.
4.2.5. 1-(2-Hydroxyethyl)-4-(2-Methyl-3,5-Diphenylpyrazolo[1,5-a] Pyrimidin-7-yl)
Piperazin-1-ium
Recently, investigations found that AMG 510 is not the only small-molecule inhibitor
that is potent in terms of the KRAS mutation. In 2019, McCarthy et al. developed a new
small-molecule inhibitor [94], which has the affinity to bind to the allosteric binding site.
This allosteric pyrazolopyrimidine-based inhibitor (†††) (Table 2) binds with the allosteric
p1 pocket of both wild-type and KRAS mutants. This new small molecule blocks the
MAPK pathway by downregulating the Raf signaling towards RAS mutation. Another
advantage of this allosteric inhibition is that it is not limited to only this specific KRAS-type
allele. It shows benefits for wild-type and GTP-bound subtypes of the KRAS oncogene.
This remarkable positive result makes this allosteric inhibitor a first-line therapy for tumor
treatment in a different range. This small-molecule allosteric inhibitor showed notably good
results in lung and oral cancer cell lines that make the allosteric pyrazolopyrimidine-based
inhibitor applicable for PDAC treatment.
4.2.6. BGB324 (Bemcentinib)
PDAC progression is directly interlinked with Axl, where the TBK1–NFkB pathway
and innate immune suppression are caused by Axl kinase signaling [106,107]. BGB324
(Table 2) is an Axl kinase inhibitor that inhibits colony formation in the PDAC cancer cell
line, and gemcitabine produces a moderate therapeutic effect in vitro. BGB324 works by
decreasing the phosphorylation of Akt, and TBK1 causes inhibition of Axl signaling [95].
An investigation showed that treatment with BGB324 in six human and three mice PDAC
cell lines achieved IC50 values ranging from 1 to 4 µmol/L. When BGB324 was administered
in combination with gemcitabine, the therapeutic efficacy was identified for a prolonged
time. A study on the murine model showed that control drugs or only gemcitabine therapy
provide therapeutic effects for not more than one day. Still, applying combination therapy
(BGB324+ gemcitabine) exerted a prolonged effect and extends the possibility of novel
treatments against PDAC [95].
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4.2.7. ABT-737
p21-activated kinase (PAK) is an effector of small GTPase Rac and cdc42 proteins.
These proteins are responsible for cell-cycle regulation, cell division, and transformation [108,109]. Studies found that inhibition of PAK4 and PAK1 suppresses the KRAS and
BRAF mutation in colon cancer in vitro. ABT-737 (Table 2) is a small-molecule inhibitor that
represses Bcl-2/Bcl-XL , resulting in the inhibition of RNAi of PAK4 and PAK1 in HCT116
colon cancer cells [96]. Although PAK1 and PAK4 phosphorylate are common substrates in
phosphorylation pathways (RAF/MEK/ERK) [110–113], they did not show any consistent
inhibition of the RAF1, MEK, or ERK signaling pathways in HCT116 colon cancer cells.
The results showed that ABT-737 treatment in PAK4 led to 43–89% reductions in 6 of 7 cells,
and the suppression of PAK1 caused 45–50% decreases in 2 of 7 cells according to the cell
proliferation assay. Interestingly, when PAK4 and PAK1 were treated simultaneously, only
PAK4 responded for seven colon cancer cell lines in the cell proliferation assay. As a result,
further investigation identified that PAK4 and PAK1 suppression were responsible for 95%
and 80% cell proliferation, respectively, in HCT116 colon cancer cell lines alone [96].
4.2.8. AZD6244 (Selumetinib)
The identification of specific inhibitors for specific biomarkers is an important strategy in cancer treatment. Tentler et al. [97] classified the biomarkers that showed therapeutic responses to the MEK1/2 pathway using the small-molecule inhibitor AZD6244
(Table 2) in KRAS-mutated colorectal cancer. They tested AZD6244 in 37 CRC cell lines
with KRAS/BRAF mutation status. They found IC50 values of ≤0.1 mmol/L in AZD6244sensitive (7 of 27 cells) and of >1 mmol/L in AZD6244-resistant (11 of 27 cells) CRC cell
lines. A further study was conducted to classify the genomic target for AZD6244. Tests
conducted using in vivo mouse model, and human model found that the KRAS mutants
had limited therapeutic options and expressed different gene array and pathway analysis [97]. The Wnt signaling pathway was overexpressed in AZD6244-resistant CRC cell
lines, indicating that this pathway might be responsible for resistance in the MEK inhibitor
and, furthermore, the Wnt pathway might be a potential target for MEK inhibitors via
modification of their structure or therapeutic activity [97].
4.2.9. NVP-BEZ235 (Dactolisib)
A small-molecule compound, NVP-BEZ235 (Table 2), was identified as a potent dual
pan PI3K/MEK inhibitor in lung cancer. Doxycycline induces p110α H1047R mutation in
human lung cancer cells [98]. P110α is a catalytic subunit that is encoded by the PIK3CA
gene and activates PI3K [114]. NVP-BEZ235 inhibits p110α H1047R mutation by blocking
the kinase activity of PI3K. A further in vivo study was conducted in the mice model to
identify the efficacy of NVP-BEZ235 by inhibiting TORC1. However, combination therapy
of NVP-BEZ235 and rapamycin successfully decreased the S6 phosphorylation of TORC1,
resulting in significant tumor suppression. However, the single treatment of NVP-BEZ235
did not respond in an in vivo study [98]. An investigation of previous research revealed
that PI3K caused KRAS mutation in the mouse model [115,116]. As a result, different
genetic alteration approaches were used in further investigations, and it was confirmed that
the downregulation of PI3K suppresses KRAS-mutated lung carcinoma, but the effect was
not so significant. Recent studies found that the inhibition of both PI3K and ERK signaling
can be highly effective in cancer treatment. As a result, the combination treatment of
NVP-BEZ235 (PI3K inhibitor) and ARRY-142886 (MEK Inhibitor) [117] showed significant
tumor suppression in KRASG12D lung cancer cells, whereas ARRY-142886 alone exerted
mild effect [98].
4.2.10. R115777 (Zarnestra or Tipifarnib)
A potent small-molecule inhibitor, R115777 (Table 2), can inhibit farnesyl transferase
signaling by inducing apoptosis in myeloma cells. RAS mutation is commonly seen in
myeloma and is activated by interleukin receptor 6 [118]. Previous studies found that
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another FTI inhibited RAS prenylation by activating growth arrest in different myeloma
cells, whereas R115777 also showed a similar mechanism in inhibiting myeloma [118]. On
the contrary, further investigation showed that R115777 inhibited cell growth following
another mechanism that did not involve inhibiting RAS prenylation. These results indicate
that R115777 follows an independent RAS mechanism [99]. Apoptosis activity was investigated in Mcl-1, Bcl-XL, and Bcl-2 antiapoptotic proteins [119], which are overexpressed in
myeloma [120,121]. It was found that R115777 suppresses Bax overexpression by disputing
mitochondrial membrane and activating endoplasmic reticulum stress. To identify the
inhibition of caspase-9-induced apoptosis, the activity of R115777 was compared to known
caspase-9 inhibitors, and the results showed a dose-dependent inhibition of caspase-9,
which indicates that R115777 induces apoptosis by inhibiting caspase-9 [99].
4.2.11. PPIN-1, PPIN-2
Targeting protein–protein interaction (PPI) is an attractive way to treat RAS mutation.
Cruz-Migoni et al. [100] identified two PPI inhibitors, PPIN-1 and PPIN-2 (Table 2), which
bind to pocket 1 near the effective binding site. However, after binding to KRAS166 G12D ,
these inhibitors cannot impair any RAS mutation due to the presence of intracellular
anti-RAS antibody fragments. Nevertheless, using a synthetic method, a new compound
can be developed by combining the two classes of RAS-binding compounds. As a result,
the inhibitor PPIN was combined with one of the RAS-binding intracellular antibody
derivatives (Abd-7), and the RAS inducer PPI was inhibited. To bind these RAS inhibitors
together, PPIN biphenyl group acted as the bait, and three crossover compounds, Ch-1,
Ch-2, and Ch-3, were synthesized. The combination of PPIN-2 and these newly synthesized
compounds bound smoothly in pocket 1, and Ch-1 and Ch-3 showed better IC50 values
(5.3 and 4.5 µM, respectively) than Abd-7 [100].
4.2.12. pan-RAS Inhibitor 3144 (RAS-IN-3144)
Investigations found that it is tough to identify specific inhibitors that bind to the RAS
protein in the appropriate binding site [122,123]. Sometimes interacting with allosteric
or adjacent binding sites, small-molecule inhibitors can produce therapeutic effects on
RAS mutation. Welsch et al. [101] synthesized the pan-RAS inhibitor 3144 (Table 2), which
showed a binding effect with the adjacent site of the KRAS oncoprotein. After passing
different experimental conditions, 3144 was found to bind with KRASG12D and KRASG12V .
Further investigation found that 3144 induced caspase activity, increased apoptosis, and
mechanistically downregulated the overexpression of the RAS effectors PI3K/AKT in
addition to RAF/MEK/ERK signaling [101]. Additionally, 3144 inhibited progression and
tumor growth in the case of RAS mutation both in vitro and in vivo. A further experiment showed its effectiveness on KRAS-mutated pancreatic cancer in a mouse model, but
significant side effects were also observed in this case [101].
4.2.13. Deltarasin
Recent studies found that Deltarasin (Table 2) downregulates the RAS/RAF signaling
pathway by inhibiting Phosphodiesterase-δ (PDEδ) binding with the hydrophobic pocket
of PDEδ, resulting in the inhibition of KRAS-harbored pancreatic ductal adenocarcinoma
(PDAC) [124,125]. As KRAS mutation is responsible for different types of cancers—lung
cancer, colorectal cancer, etc.—more investigation is desirable for inhibiting KRAS oncogenes. The majority of lung cancer incidents happen for KRAS mutants [126]. As a result,
Leung et al. [127] first identified that deltarasin induces apoptosis significantly, both in vitro
and in vivo, in lung cancer cells. It also induces autophagy in lung cancer cells by inhibiting
the MAPK/mTOR signaling pathway. It was also shown that when deltarasin is treated
with 3-MA (autophagy inhibitor), it increases autophagic properties and produces more
intracellular ROS levels, thus protecting against further autophagy.
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4.2.14. (2. R,4aR)-3-Acryloyl-11-chloro-9-fluoro-10-(6-fluoro-2-hydroxycyclohexa-2,4dien-1-yl)-2,6-dimethyl-2,3,4,4a-tetrahydro-1H-pyrazino [1’,2’:4,5] Pyrazino[2,3-c]
Quinolin-5(6H)-one
Kettle et al. [103] identified a potent and selective KRASG12C inhibitor (Table 2) by
introducing a key methyl group to the piperazine. The KRASG12C allele constitutes an
“Achilles heel” where the small-molecule inhibitors can bind covalently, bind the mutant
cysteine, and create an allosteric pocket on GDP-bound RAS. The strategy modifies the
weak KRASG12C inhibitor that binds to this specific site, increasing the potency of the
newly synthesized compound. The in vivo study showed significant tumor regression in
KRASG12C mutant Miapaca2 xenografts.
4.2.15. SML-8-73-1 and SML-10-70-1
Min Lim et al. [104] found that guanine-based small-molecules covalently bind in the
guanine-binding site and that binding with covalent inhibitors can irreversibly inhibit KRAS
signaling. KRAS mutations occur near the usual position of the gamma phosphate of the
GTP-binding site. After conducting the X-ray crystallography and molecular docking study,
a promising candidate (SML-8-73-1) was synthesized, which binds the specific guaninebinding site. To improve the potency, a new analog of SML-8-73-1 (Table 2) was developed
by modifying the beta phosphate as an alanine ester phosphoramidite, resulting in SML-1070-1(Table 2). Moreover, the new derivative, SML-8-73-1, produced antiproliferative effects
on the KRASG12C -mutated cell line.
4.3. Oxoheterocyclic Small-Molecule RAS Inhibitors
Identification of major pharmacophore(s) and biomolecular target based on the structure of oxoheterocyclic RAS inhibitors are shown in Table 3.
Table 3. Oxo heterocyclic small-molecule RAS inhibitors.
Cancer Type

Compound Name

Structure

Major Pharmacophore(s)

Biomolecular
Target (M/A)

Reference

Inhibits tumor
progression,
decreasing CRAF,
ERK, and AKT
phosphorylation

[102]

Lung cancer

NHTD

Tetrahydrodibenzofuran,
2,4Dihydroxybenzohydrazide

Unknown

PD98059

Chromenone

MEK inhibitor

[128]

Colorectal cancer

Wortmannin

Furoindenoisochromene

Suppresses
upregulation
of PI3K

[129]

4.3.1. NHTD
The binding of KRAS with the prenyl-binding protein (PDEδ) produces its oncogenic
property. Therefore, inhibition of PDEδ can be an effective path for KRAS-induced cancer
treatment [125,130]. The small-molecule prenyl inhibitor NHTD (Table 3) blocks the prenylbinding pocket as well as localization to the plasma membrane, resulting in the disruption
of oncogenic KRAS-PDEδ binding [102]. NHTD also can induce apoptosis in different types
of lung cancer cells. In the in vivo study, NHTD inhibited tumor progression in xenograft
and mouse models by decreasing CRAF, ERK, and AKT phosphorylation. Computational
molecular docking studies identified a specific binding site for a particular small molecule.
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4.3.2. PD98059
It was reported that colon cancer is associated with two genetic events: the Wnt
signaling pathway and KRAS mutation. Additionally, vascular endothelial growth factor
(VEGF) is operated by both genetic factors [128]. KRAS exerts an oncogenic effect by
activating multiple Raf/MEK/ERK and PI3K pathways. An experiment was conducted
with LY294002 and PD98059 (Table 3) on the ERK and PI3K pathways to determine if the
Wnt signaling pathway follows similar pathways for the association of colon cancer. The
results indicated that the PI3K effector pathway was critical for the KRASval12 -mediated
stimulation of Wnt signaling.
Additionally, further investigation was conducted to determine if both KRAS and
Wnt signaling regulate the phosphorylation of TCF4. The results showed that β catenin
formed a complex in both the phosphorylated and unphosphorylated form, but KRAS did
not control the phosphorylation of TCF4. β catenin is the key regulator for Wnt signaling;
KRAS regulates the stability of β catenin. Moreover, KRAS controls GSK-3 β Activity
independently of Serine-9 Phosphorylation. Finally, these two genetic factors follow a
unique interaction between two oncogenic pathways by which KRAS increases signaling
via the Wnt pathway in colon cancer [128].
4.3.3. Wortmannin
Wortmannin (Table 3) is a PI3K inhibitor that covalently binds to the p110 subunit of PI3K; it irreversibly inhibits PI3K and decreases AKT phosphorylation [131,132].
Int. J. Mol. Sci. 2022, 23, x FOR PEER REVIEWBialkowska and colleagues [129] identified that wortmannin decreased
18 of 39
pAKT levels in
DLD-1 cells via a reduction in KLF5 levels. Recent studies found that PI3K/AKT activation
is often associated with colorectal cancer and enhanced colorectal cancer development [133].
via a reduction
in KLF5
levels.colorectal
Recent studies
found
PI3K/AKT the
activation
is often of PI3K in a doseWortmannin
inhibits
cancer
by that
suppressing
upregulation
associated with colorectal cancer and enhanced colorectal cancer development [133].
dependent manner.
Wortmannin inhibits colorectal cancer by suppressing the upregulation of PI3K in a dosedependent manner.
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Table 4. Mixed heterocyclic small-molecule RAS inhibitors.
Compound
Name
Compound
Name

Structure
Structure

&
&

KYA1797K (ab229170)

Targeted Enzyme
CancerType
Type Targeted Enzyme Reference
Cancer
(M/A)
(M/A)

Inhibition of 2 β-1,6
Chlorofluorophenyl,
Inhibition of 2 β-1,6 NChlorofluorophenyl, MorPancreatic can- N-acetylglucosamiMorpholine,
Quinazoline,
acetylglucosaminyltransferase
pholine, Quinazoline,
Pyri- Pancreatic cancer
[134]
cer
nyltransferase
Pyridine,
(GCNT3)
dine,Benzofuranone
Benzofuranone
(GCNT3)

Talniflumate
Talniflumate
+ Gefitinib
+ Gefitinib

CPD-0857 and
KY1022
CPD-0857 and KY1022

Major
Pharmacophore(s)
Major
Pharmacophore(s)

Inhibition
of
Pyrazole, Pyran,
Inhibition
of Wnt/β-catenin,
Colorectal cancer
RAS/ERK, and PI3K/AKT
Thienopyrimidine
Pyrazole,
Pyran, Thienopy- Colorectal can- Wnt/β-catenin,
[135]
rimidine
cer
RAS/ERK, and
PI3K/AKT

Nitrophenyl, Furan, Thioxo- Colorectal canthiazolidin-4-one
cer

Unknown

[136]

Reference

[134]

[135]
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Table 4. Cont.
Major Pharmacophore(s)

Cancer Type

Targeted Enzyme
(M/A)

Reference

KYA1797K (ab229170)

Nitrophenyl, Furan,
Thioxothiazolidin-4-one

Colorectal cancer

Unknown

[136]

0375-0604 (KRAS
inhibitor-9 or
DUN09716)

Benzothiazolylthio-3chloroaniline

Unknown

Inhibition of KRAS mutation
by downregulating
RAF/MEK/ERK and
RAF/PI3K/AKT signaling
pathways

[137]

7773

Tetrazole, Piperidine,
Benzodioxole

Lung cancer

Binding with hydrophobic
surface of Igf2bp1 in KH3 and
KH4 domain inhibits KRAS
mutation.

[138]

NSC-658497

Thioxothiazolidine,
Chromane-2,4-dione,
Nitrophenyl

Unknown

Binding with hydrophobic
pocket downregulates
pERK1/2 and pAKT signaling

[139]

JNJ-74699157

Pyrazolopyrimidine,
Benzocyclononaphanone

Unknown

KRASG12C inhibitor

Phase I
Clinical trial
completed

Compound Name

Structure

4.4.1. Talniflumate + Gefitinib
Mucin is one of the major culprits that hinder drug delivery, and several clinical
studies identified that mucin is overexpressed in KRAS-driven pancreatic cancer in mouse
and human models [140–143]. Enzyme 2 β-1,6 N-acetylglucosaminyltransferase (GCNT3)
is recognized as a novel core mucin-synthesized enzyme and targeting this enzyme could
decrease the overexpression of mucin [134]. KRAS mutation with p48Cre/+ -LSL-KRASG12D/+
GEM upregulates the mucin concentration in pancreatic intraepithelial neoplasia (PanIN)
and PDAC. Further study found that GCNT3 enzyme is abnormally expressed from GEM in
pancreatic cancer as compared to the pancreases under normal conditions, resulting in high
mucin formation. Therefore, GCNT3 is used as a novel target to inhibit the overexpression of
mucin in pancreatic cancer. Talniflumate (Table 4) is a mucin inhibitor with a good binding
capacity with GCNT3 following in-silico validation. The docking score of talniflumate
is very impressive compared to the known ligand GALB1, 3GALNAC. Further study
confirmed that talniflumate, after binding with GCNT3, inhibits the protein expression
of GNCT3 and significantly decreases the overexpression of mucin. Further investigation
of the EGFR inhibitor (gefitinib) (Table 4) confirmed the occurrence of remarkable tumor
regression in PDAC and PanIN, with a significant decrease in mucin expression.
4.4.2. CPD0857 and KY1022
Wnt/β-catenin and RAS-MAPK signaling are the central pathways for KRAS, and
APC mutation causes drug-resistant colorectal cancer (CRC) [144]. Recently, Jung Kyu Choi
and colleagues [135] identified a novel compound with inhibitory capacity against both the
Wnt/β-catenin and RAS-MAPK signaling pathways in drug-resistant CRC. Mechanistically,
CPD0857 (Table 4) does not downregulate β-catenin and RAS protein signaling, indicating
that it might follow a different mechanism. After observing the apoptotic activity of
CPD0857, the results suggested that the inhibition of cell growth and HCT116 happened
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due to PI3K/AKT suppression, and in vivo tumor suppression occurred following the
inhibition of Wnt/β-catenin and RAS/ERK signaling [135]. A previous study found that
another small-molecule inhibitor, KY1022 (Table 4), destabilizes both Wnt/β-catenin and
RAS/MAPK signaling. This study explicitly targeted KRASG12D in a mouse model, and
the results showed a significant decrease in tumor growth [145].
4.4.3. KYA1797K
Another small-molecule KYA1797K (Table 4), was identified as a potent inhibitor of
cetuximab-resistant KRAS-driven colorectal cancer [137]. This small-molecule inhibitor
functions by disrupting β-catenin and RAS via GSK3β activation. KYA1797K overcame
the cetuximab-resistant KRAS mutation when applied to the cetuximab-resistant CRC
cell, but it showed dose-dependency in inhibiting the mutation. In vivo analysis was
also performed to observe the cetuximab-resistant KRAS-harboring CRC tumor in the
Xenograft mouse model [137]. There was no tumor suppression when cetuximab was solely
applied to the mouse model. On the other hand, KYA1797K alone or combination with
cetuximab showed significant regression of tumor growth. A further experiment conducted
on an ApcMin/+/KRASG12DLA2 mouse model showed tumor growth inhibition, but also
demonstrated cetuximab resistance [137].
4.4.4. 0375-0604
Xie et al. [146] synthesized a new small-molecule inhibitor, 0375-0604 (Table 4), which
exerts a binding effect with the switch region (switch-I, II) of the KRAS-harbored cell line.
The significant characteristic of 0375-0604 is that it comprises two hydrogen bonds that
bind with the backbone of Met67 and the side chain of Glu37 in the switch I and switch
II pocket, respectively. Moreover, after binding to the pocket, 0375-0604 inhibits KRAS
mutation by downregulating RAF/MEK/ERK and RAF/PI3K/AKT signaling pathway.
It induces apoptosis, leading to the arrest of the G2/M cell cycle in the KRAS-harbored
NSCLC cell line.
4.4.5. 7773
Oncofetal RNA-binding protein (Igf2bp1) is responsible for different types of cancer [138] and can synergize mutation to KRAS. Researchers synthesized the small-molecule
inhibitor 7773 (Table 4), which can bind with the hydrophobic surface of Igf2bp1 in the
KH3 and KH4 domain and inhibit the binding of KRAS 6 RNA in vitro. Targeting Igf2bp1,
this small-molecule inhibitor can reduce KRAS mRNA, resulting in a decrease in KRAS
protein and downregulation of signaling, thereby decreasing cell growth. Thus, it might be
a potential therapeutic target in cancer treatment.
4.4.6. NSC-658497
RAS signaling is activated by SOS1 (guanine nucleotide exchange factors) [139], which
is responsible for receptor tyrosine kinase signaling to RAS. A small-molecule inhibitor,
NSC-658497 (Table 4), was identified as interacting with SOS1, competitively inhibiting
SOS1–RAS interaction, and suppressing SOS1 GEF activity following dose-dependency.
Mechanistically, the structure of NSC-658497 comprises aromatic benzopyran and the polar
nitrophenyl moiety. A benzopyran derivative interacts with the hydrophobic pocket of
SOS1, which acts as bait within the active site of SOS1. In contrast, the polar nitrophenyl
moiety may interact with the outside of the hydrophobic pocket of SOS1. Following this
mechanism, NSC-658497 showed an inhibitory effect against RAS oncogenic protein. NSC658497 was also found to inhibit cell proliferation in a murine model by downregulating
the pERK1/2 and pAKT signaling pathways.
4.4.7. JNJ-74699157
JNJ-74699157 (Table 4) was identified as a KRASG12C inhibitor and was found to
covalently bind to KRASG12C at the critical mutant residue cysteine 12, locking the GTPase
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in an inactive state and inhibiting KRAS signaling [147]. This small-molecule inhibitor
is now in a phase-I clinical trial. The clinical trial of JNJ-74699157 was reported to be
completed within one year, with only 10 participants and no results published [148].
4.5. Carbocyclic Small-Molecule RAS Inhibitors
Carbocycles are also very important as heterocycles in drug discovery research. After
meticulous investigation, small-molecule RAS inhibitors with the carbocyclic structure are
shown in Table 5.
Table 5. Carbocyclic small-molecule RAS inhibitors.
ID

Structure

PKF115-584
(Calphostin C)

Kobe0065
+
Kobe2602

Kobe0065

Major Pharmacophore(s)

Cancer Type

Biomolecular Target
(M/A)

Reference

Tetramethoxy-3,10-dioxo-3,10dihydroperylen-1-yl) propan-2-yl
benzoate

Colorectal cancer

Downregulates
MAPK and RalA
signaling

[149]

2,6-dinitro-4(trifluoromethyl)phenyl,
Carbothioamide, Halophenyl

Unknown

Inhibits HRASG12V
and KRASG12V
mutation

[150]

Myeloid leukemia

Inhibits
isoprenylcysteine
carboxylmethyltransferase
(ICMT)

[151]

Bladder cancer
(salirasib)

Inhibits glycolysis
and oxidative
phosphorylation
pathways

Kobe2602
Phenylacetamide

†††††

Salirasib
+
FTS, Salirasib

Salirasib

Trimethyldodecatrienylthiobenzoic
acid

[152]
[153]

FTS, Salirasib

††††† = 3,3’-(ethylazanediyl)bis(N-phenylpropanamide).

4.5.1. PKF115-584 (Calphostin C)
Combination therapy of PKF115-584 (Table 5) (β-catenin inhibitor) and transfarnesylthiosalicylic acid (FTS, salirasib) (RAS inhibitor) can inhibit both Wnt-associated and
KRAS-associated colorectal cancer [154,155]. Although both inhibitors can solely suppress
colorectal cancer, combination therapy synergizes their inhibitory effect. The investigation
found that when this combination drug therapy was applied to two colorectal cancer cells
carrying both β-catenin and the KRAS mutation, the Ls174T cells showed inhibition of
MAPK signaling while the DLD-1 cells inhibited FOS expression, which downregulates
RalA [149]. This combination therapy also showed significant cell growth-inducing apoptosis, which occurred because of the downregulation of survivin activity. In addition, a
combination of these two inhibitors suppressed tumor growth, and their synergistic effect
was specific to the KRAS and Wnt mutant as they did not show any effect on wild-type
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KRAS. It was also identified that treatment with these combined inhibitors requires a small
dose and exerts minimal side effects [149].
4.5.2. Kobe0065 + Kobe2602
Identification of a suitable or specific binding pocket on the surface of the RAS proteins
where the therapeutically active small-molecule drug can bind is a promising strategy for
treating RAS-related cancer. Thus, Shima et al. [150] identified a therapeutic family of
small-molecule inhibitors (Kobe0065 and its analog Kobe2602) (Table 5) that can inhibit
multiple types of RAS mutation. A previous study found that small-molecule inhibitors
can inhibit SOS expression by binding with KRAS-GDP [156]. After in silico validation,
it was identified that Kobe0065 and Kobe2602 could inhibit RAS activity both in vitro
and in vivo, binding with HRAS·GTP-c-Raf-1. Both inhibitors efficiently downregulated
the phosphorylation of MEK and ERK. These downregulations inhibited the HRASG12V
mutation in NIH 3T3 cells. In addition, they showed antitumor activity on KRASG12V
mutated SW480 colon cancer cells when orally administered.
4.5.3. 3,3’-(Ethylazanediyl)bis(N-phenylpropanamide)
Methylation of the carboxy-terminal amino acid is one of the post-transcriptional modifications of oncogenic RAS protein that is activated by isoprenylcysteine carboxylmethyltransferase (ICMT) [157]. The inhibition of isoprenylcysteine carboxylmethyltransferase
(ICMT) can be an effective pathway for RAS-associated cancer treatment. Marín-Ramos
et al. [151] identified a potent small-molecule inhibitor (Table 5) that can impair four RAS
isoforms (HRAS, KRAS4A, and -4B, and NRAS). The activity of compound 3 was tested
on KRAS (G12C, G12D, G12V, and G13D) isoforms and two NRAS-mutated cell lines
(significantly found in myeloid leukemia and myeloma [158]); compound 3 demonstrated
significant cytotoxic activity for all the isoforms, with the most potent IC50 value being
observed in the NRAS (Q61K) isoform [151].
4.5.4. Salirasib + FTS, Salirasib
HRAS upregulation is frequently identified in bladder cancer (BC) [159]. Salirasib
(Table 5) has been identified as a potent RAS inhibitor in different types of cancer but
requires a high concentration for inhibition. Sugita et al. [152] investigated the therapeutic
activity of salirasib in HRAS-mutated BC. The authors investigated the binding of salirasib
with siRNA targets HRAS, and it was found to result in the inhibition of cell proliferation
invasion. Proteomic analysis showed that salirasib inhibits the glycolysis and oxidative
phosphorylation pathways. Another series comprising the RAS inhibitor S-trans,transfarnesylthiosalicylic acid (FTS salirasib) (Table 5), which interacted with the RAS membrane,
showed a transformation. Goldberg and co-workers developed [153] a new derivative
of FTS salirasib where the carboxyl group was modified by esterification and amidation.
They identified all the modified FTS salirasib amides, and it was found that two esters
significantly inhibited the growth of Panc-1 and of U87 cells, where at least one RAS
isoform showed a chronic effect. They also identified that the modified FTS salirasib did
not produce any toxicity in Panc-1 and U87 cells.
4.6. Miscellaneous Small-Molecule RAS Inhibitors
There are some small-molecule RAS inhibitors that are in clinical trials. Details about
these RAS inhibitors have not been published yet. We also identified one thioheterocyclic
small molecule RAS inhibitor. In Table 6, we classified these RAS inhibitors as miscellaneous
small-molecule RAS inhibitors.
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Table 6. Miscellaneous small-molecule RAS inhibitors.
ID

Structure

ML264

Major Pharmacophore(s)

Cancer Type

Targeted
Enzyme/
(M/A)

References

Dioxidotetrahydro-2Hthiopyran,
Chlorophenyl

Colorectal cancer

KLF5 inhibitor

[160]

GDC-6036

Unpublished

Unpublished

KRASG12C inhibitor

LY3499446

Unpublished

Unpublished

KRASG12C inhibitor

D-1553

Unpublished

Unpublished

KRASG12C inhibitor

Phase I
Clinical trial
(Genentech Inc)
Phase I and II
Clinical trial
(Eli Lilly)
Phase I
Clinical trial
(InventisBio Co., Ltd.,
Shanghai, China)

4.6.1. ML264
Krüppel-like factor 5 (KLF5) is a transcription factor that is overexpressed in proliferating intestinal crypt epithelial cells. KLF5 acts as a mediator of the RAS/MAPK and
WNT signaling pathways under homeostatic conditions, and it increases their oncogenic
function in intestinal adenomas. Sabando et al. [160] identified a novel KLF5 inhibitor
with a therapeutic effect in colorectal cancer. Treatment with ML264 (Table 6) in DLD-1
and HCT116 colorectal cell lines showed a regression in the protein levels of KLF5 that
paralleled a reduction in the levels of the transcription factor early growth response 1
(EGR1), which is a direct effector of KLF5 expression. The application of ML264 in a nude
mice model inhibited proliferation in colorectal cancer.
4.6.2. GDC-6036
GDC-6036 is a c inhibitor. The combination of GDC-6036 with atezolizumab causes
intracellular interactions (ICI), its combination with cetuximab or erlotinib blocks EGFR,
and the combination of GDC-6036 with bevacizumab inhibits VEGF. GDC-6036 is also in
phase I clinical trial. However, the structure of this compound is not disclosed [148].
4.6.3. LY3499446
LY3499446 is another KRASG12C inhibitor that is combined with abemaciclib, and it
inhibits the regulation of CKD4. This small-molecule inhibitor showed promising results in
phase I clinical trials. Unfortunately, in 2020, LY3499446 was terminated due to unexpected
toxicity [148,161].
4.6.4. D-1553
D-1553 also inhibits KRASG12C mutants. This inhibitor is in a phase I clinical trial.
Details about these inhibitors have not been published, and data from ongoing clinical
trials have not been reported [148,161].
5. Small-Molecule Natural Products as RAS Inhibitors
Various anticancer compounds have been identified from natural sources. Researchers
identified that from 1981 to 2019, the US federal drug administration (FDA) approved
185 small-molecule anticancer drugs to treat various types of cancer. Among these 185
small-molecule anticancer drugs, 43% are from natural product derivatives, and 18% are
unaltered natural product anticancer drugs [162–164]. These data highlight that natural
products comprise a vast research area in cancer treatment. Herein, we describe natural
product RAS inhibitors and their molecular mechanisms of action.
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5.1. Natural Product RAS Inhibitors with Heterocyclic Skeleton
5.1.1. Quercetin
Quercetin (Figure 3) is a dietary flavonoid found in tea, onions, grapes, wines, and
apples [165]. Investigations found that quercetin can inhibit human colorectal cancer by
inhibiting the expression of the p21 RAS mutant. An immunocytochemical study found
that the administration of 10 µM quercetin reduces p21 KRAS in colon cancer cells and in
initial colorectal cancer. This quercetin treatment is time and concentration-dependent. At
twenty hours, 10 µM quercetin treatment induces 50% p21 KRAS inhibition. Interestingly,
quercetin produces a similar therapeutic effect for KRAS, HRAS, and NRAS oncoproteins,
and their effect does not depend on the cell cycle position of colon cancer [165]. Zhang and
co-workers [166] investigated the possibility that quercetin also inhibits the cell growth and
metastasis of osteosarcoma. Although quercetin administration solely decreases osteosarcoma, its combination with cisplatin, a well-known chemotherapeutic agent, synergizes
with the quercetin activity in osteosarcoma. Additionally, treatment with 5 µM quercetin in
143B cells did not show cell viability, whereas significant cell viability was observed with
10 µM quercetin. Furthermore, when 5 µM cisplatin was administrated to 143B cells, the
IC50 value was 6.12 M. In the meantime, cotreatment with 5 µM of quercetin and cisplatin
showed an IC50 of 4.21, which indicates that quercetin enhanced the cisplatin sensitivity
of 143B. Cisplatin showed resistance towards osteosarcoma, and MiR-217 decreased the
resistance of osteosarcoma [167]. Treatment with quercetin and/or cisplatin upregulates
MiR-217, but treatment with KRAS downregulates mRNA and protein levels.

Figure 3. Heterocyclic natural product RAS inhibitors.
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5.1.2. Artemidolide C
Artemidolide is a dimeric sesquiterpene lactone and FPTase inhibitor. It is an (A-D)
series that is isolated from Artemisia spp. [168]. In vitro, artemidolide C (Figure 3) treatment showed dose-dependent inhibition, and approximate growth inhibition followed
the administration of 1.3–8.1 µM. The growth inhibition in three human cancer cell lines
(colon, breast, and CNS) showed sensitivity when treated with artemidolide C, but the
renal tumor cell line A498 showed resistance [168]. An earlier study identified that, due to
the presence of the α-methylene-γ- lactone group, sesquiterpene lactones exhibit antitumor
activity [169]. However, the α-methylene-γ- lactone unit in artemidolide did not affect the
inhibition of FPTase activity, but the problem was solved when hydrogenated artemidolides
exerted low antiproliferative activity. Furthermore, in vivo antiproliferative activity in nude
mice showed that artemidolide C inhibits tumor growth [168]. Another study showed that
treatment with artemidolide C in a HRAS-mutated cell line resulted in degradation of the
HRAS protein [170].
5.1.3. Statins
Mevalonate intermediates, including farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), which are responsible for activating RAS proteins, were
potentially inhibited by statins in pancreatic cancer [171]. Simvastatin (Figure 3) treatment in MiaPaCa-2 human pancreatic cancer cells showed that 200 genes were affected
by simvastatin treatment. This was due to the interaction between FPP and simvastatin.
However, it was observed that the normalization of the expression of KRAS-related genes
and the GFP-KRAS protein trafficking was partially prevented by the addition of any of
the mevalonate pathways intermediates. Finally, the addition of FPP or GGPP normalized
simvastatin-treated altered genes. Therefore, KRAS protein trafficking can be successfully
inhibited by statin treatment in pancreatic cancer [171].
5.1.4. Manumycin A
Exosomes are necessarily involved in the trafficking of oncogenic factors and the
neoplastic alteration of stem cells, resulting in cancer progression [172,173]. Manumycin A
(Figure 3) (MA) is a natural macrolide antibiotic isolated from Streptomyces parvulus and has
been identified as an exosome that can be targeted therapeutically. To determine the nontoxic dose of manumycin A and evaluate the effect of exosome biogenesis, MA was applied
to RWPE-1 and PC-3 cells, and no effect was observed, while approximately 8% and 10%
cell death was observed on C4-2B and 22Rv1 cells, respectively [174]. However, using the
EV analysis based on TRPS, the Nanosight300 and NanoFACS analyses reported that MA
selectively inhibits the biogenesis and secretion of exosomes in some castration-resistant
prostate cancer (CRPC) cells. In addition, MA inhibited exosome biogenesis and secretion
by downregulating the RAS/Raf/ERK1/2 pathway in CRPC cells. Finally, MA inhibits
exosome biogenesis and secretion, suppressing RAS signaling pathways (RAS/Raf/ERK).
5.1.5. Gliotoxin
Liver injury happens due to an overdose of analgesic and antipyretic acetaminophen
(APAP). Article [175] described that hepatotoxicity due to an excessive dose of APAP
activates RAS mutation in mice models. Gliotoxin (Figure 3) is a sulfur-containing mycotoxin produced by various pathogenic fungi, including Aspergillus fumigatus [176]. As a
potent farnesyl transferase inhibitor (FTI), Gliotoxin decreased RAS overexpression upon
APAP overdosing. It was also identified that RAS activation concomitantly increased with
hepatotoxicity [175].
Furthermore, APAP dosing reduces the hepatic glutathione amount, but manumycin
A (inhibiting the RAS GTP and ALT interaction) treatment does not affect this. Additionally,
the results suggested that RAS activation is regulated by JNK phosphorylation because
APAP dosing induces JNK phosphorylation, and the application of manumycin A signifi-
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cantly decreases JNK phosphorylation. After APAP dosing, gliotoxin treatment reduces
serum amounts of ALT and IFN-γ and inhibits RAS activation [175].
5.1.6. Preussomerin G
In 1991, Holly A. and colleagues isolated a group of preussomerins (A–F) (preussomerin
G, Figure 3) from the coprophilous fungus Preussia isómera [177]. Farnesyl protein transferase is responsible for RAS farnesylation (p21), which is associated with the RAS plasma
membrane and helps to produce RAS signaling. Singh et al. [178] isolated preussomerins
and deoxipreussomerins from the extract of a dung-inhabiting coelomycetous fungus from
Chaco Province, Argentina, which has inhibitory function towards RAS farnesylation.
5.1.7. Pepticinnamin E
Pepticinnamin E (Figure 3) is another FPTase inhibitor. A series of Pepticinnamins
were isolated from the culture broth of Streptomyces sp. OH-4652(18). Among them, pepticinnamin E is the primary product that contains a rare N-terminal cinnamoyl moiety
and several nonproteinogenic amino acids. All isolated pepticinnamin showed a potent
inhibitory property towards FTase with IC50 values 0.1–1.0 µM, but pepticinnamin C
produced the strongest inhibition. Furthermore, pepticinnamin E exerts an effect of competitively binding with the p21 RAS protein and non-competitively binding to the substrate
farnesyl pyrophosphate [179]. Another study identified a strong reduction in FPTase E,
which is expected to treat cancer and malaria [180]. Thutewohl et al. [181] found pepticinnamin E induces apoptosis in RAS-mutated cell lines, which is connected to the inhibition
of FTase activity. They identified 51 analogs of pepticinnamin. Overall, twenty compounds
showed an inhibitory effect with an IC50 value of 1 µM.
5.1.8. Bryostatin-1
Protein kinase C (PKC) phosphorylates S181 into the polybasic region that promotes
the rapid dissociation of KRAS in the plasma membrane and has an association with the
outer membrane of mitochondria where phospho-KRAS interact with Bcl-XL . The PKC
agonist accelerates the apoptosis of cells altered with the KRAS oncogene. KRAS, with a
phosphomimetic residue at position 181, induces apoptosis via a pathway that requires
Bcl-XL [182]. Bryostatin-1 (Figure 3) is a cyclic macrolide that is isolated from the marine
bryozoan Bugula neritina [183]. Moreover, Bryostatin-1 is a PKC agonist [184] that inhibits
KRAS-dependent cell transformation and growth in an S181-dependent manner. An in vivo
study showed that bryostatin-1 was efficient against tumors in nude mice containing
oncogenic KASG12V , but in KRASG12V181A -driven tumors, it had reduced activity [182].
5.1.9. Piperlongumine
Piperlongumine (PL) (Figure 3), a natural alkaloid present in Piper longum Linn, has
been reported to exhibit notable anticancer effects in various in vitro studies. Kumar and
colleagues [185] first identified a chemo-preventive effect of PL in colon cancer-infected
animal models. PL showed significant antineoplastic activity towards colon cancer cell
growth by targeting RAS proteins and the PI3K/Akt signaling pathway. It was also
identified that PL blocked the cell cycle progression at the G2/M phase and increased the
mitochondrial apoptotic pathway by downregulating Bcl-2 levels. Moreover, PL showed
liver and kidney toxicity.
5.1.10. Confluentin
Yaqoob et al. [186] isolated three compounds, confluentin (Figure 3), grifolin, and
neogrifolin, from a methanolic extract of the terricolous polypore of Albatrellus flettii (British
Columbian mushroom), which showed cell viability. However, the cell viability mechanism
of this novel molecule is not very well established. In a cytotoxic study, the confluent
showed IC50 values of 25.9 ± 2.9 µM (n = 3), 33.5 ± 4.0 µM (n = 3), and 25.8 ± 4.1 µM
(n = 3) against HeLa, SW480, and HT29 cells, respectively [186]. Moreover, they identified
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confluentin-induced apoptosis for the first time, with a cell-cycle arrest at the G2/M phase
in SW480 human colon cancer cells. Additionally, KRASG12D , containing the SW480 human
colon cancer cell line, was used to investigate the KRAS inhibition of these three molecules.
Confluentin showed a more significant effect than grifolin and neogrifolin, but in the HT29
cell line, which contains wild-type KRAS, a similar inhibitory effect against the KRAS
mutation was observed for all three compounds. Finally, using an in vitro fluorescence
polarization method, it was found that confluentin inhibits the physical interaction between
IMP1 and KRAS RNA [186].
5.1.11. Swinhopeptolides
Two new cyclic depsipeptides named swinhopeptolides A and B were isolated from
the marine sponge Theonella swinhoei cf. verrucosa, collected from Papua New Guinea [187].
Both compounds have 11 diverse amino acid residues and 13-carbon polyketide moieties
attached at the N-terminus. To identify the effect on RAS-Raf protein–protein interactions
of Swinhopeptolides A (Figure 3) and B, a cell-based Bioluminescence Resonance Energy
Transfer (BRET) was performed. The results showed that swinhopeptolides A and B
effectively inhibited RAS-Raf protein–protein interaction with IC50 values of 5.8 and 8.5 µM,
respectively [187]. Moreover, Swinhopeptolides A and B exhibited potential RAS/Raf
signaling pathway suppression.
5.1.12. Avicin G
Avicin G (Figure 3) is a plant-derived triterpenoid saponin from Acacia victoriae; it
mislocalizes KRASG12V from the Plasma membrane (PM) and disrupts the PM spatial
organization of oncogenic KRAS and HRAS by depleting their phosphatidylserine (PtdSer)
and cholesterol contents, respectively, at the inner PM leaflet [188]. Further investigation
suggested that avicin G inhibits KRASG12V and HRASG12V mutation by downregulating the
pERK signaling pathway and pAkt, but more inhibition was observed for KRASG12V cells.
Next, a cell proliferation assay was performed on human pancreatic ductal adenocarcinoma
(PDAC) cells and non-small-cell lung carcinoma (NSCLC) cells. The results showed significant growth inhibition for both types of the cancer cell line. Previous research identified
that lysosome activity is vital for KRAS-driven cancer growth, but avicin G [189,190] blocks
the lysosome activity by elevating lysosomal PH and inhibiting the phosphorylation of
ERK signaling. It was also identified that Avicin G is a potent SMase inhibitor. It exerts a
potential inhibitory effect on acid and neutral SMase [188].
5.2. Natural Product RAS Inhibitor with Carbocyclic Skeleton
5.2.1. Prostratin
Prostratin (Figure 4) is a phorbol ester, which was first isolated from the bark of the
mamala tree of Samoa, Homalanthus nutans (Euphorbiaceae) [191]. Prostratin inhibits KRAS
and HRAS tumor growth by suppressing non-canonical Wnt/Ca2+ signaling. Comparing
KRAS and HRAS, KRAS produces more tumorigenesis, although they have a comparable level of canonical RAS signaling. The reason for this is the ability to induce tumor
initiation that is directly related to the ability of KRAS to suppress Fzd8-mediated noncanonical Wnt/Ca2+ signaling. In the KRASG12V mutation, Fzd8 was downregulated, and
the CaMKii level was decreased more significantly than that of HRASG12V , resulting in the
phosphorylation of threonine 286. Therefore, prostratin (PKC activator) interrupts KRAS
calmodulin-binding that increases the level of Fzd8, thereby inhibiting KRAS mutation in
pancreatic cancer cells [191].
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Figure 4. Carbocyclic natural product RAS inhibitors.

5.2.2. D-Limonene
Farnesyl protein transferase (FPTase) is an intermediate of the mevalonate pathway,
which contains the isopropyl group. The interaction of FPTase with a potent inhibitor can
repress malevolent pathways, resulting in the inhibition of transforming characteristics of
the RAS mutant. D-Limonene (Figure 4) is a common monoterpene that can inhibit FPTase,
and has been identified in essential oils of orange, lime, grapefruit, lemon, mandarin, and
many other plants. To determine the FTPase inhibition activity, D-Limonene and some
other compounds were applied to partially purified FPTase from LLC-PK 1 cells [192]. The
results suggested that among all the tested compounds, D-Limonene, TD-I, TD-I1, and
gallotannin produce an inhibitory effect towards FPTase but in a dose-dependent manner.
To identify the cell proliferation activity, D-Limonene, TD-I, TD-I1, and gallotannin were
tested on W1-38, CACO, A549, and PaCa cells; significant cell proliferation was identified
for all the cell lines and the effects on PaCa cells were due to the inhibition of P21RAS
membrane association. Additionally, the administration of D-Limonene on A549 cells
showed moderate HRAS inhibition. Moreover, western blot analysis showed that DLimonene also has an increased cytotoxic effect [192].
Another study found that D-Limonene significantly affected skin tumor growth in
mouse models by inhibiting 12-O-tetradecanoylphorbol-13-acetate (TPA) [193]. The development of mouse skin tumor was initiated with 7,12-dimethylbenz[a]anthracene (DMBA)
and went to the progression state because of 12-O-tetradecanoylphorbol-13-acetate (TPA).
In comparison to TPA treatment [194] (previously studied), topical treatment with DLimonene (12.30 h) in a mouse model showed only 27% and 9% increases in the weight
of the skin paunches, whereas TPA (12 h) showed an increase of 48% [193]. Similarly, DLimonene treatment significantly reduced COX-2-positive cells in the epidermis. Additionally, the application of D-Limonene suppresses the RAS, Raf signaling, and phosphorylation
of extracellular protein kinase in the case of DMBA-/TPA-induced tumors [193].
5.2.3. Methyl Linderone
Methyl linderone (ML) (Figure 4) is a cyclo-pentenedione isolated from the fruits of
Lindera erythrocarpa (family Lauraceae). Yoon et al. [195] identified that treatment with
ML inhibits breast cancer. After performing a cell viability assay, they found that 10 µM
is the nontoxic dose of ML. To study the effect of ML in invasion and migration, 12-Otetradecanoyl phorbol-13-acetate (TPA)-stimulated MCF-7 cells were used. The finding
was that TPA-stimulated invasion and migration were inhibited by MA, but in a dosedependent manner. Furthermore, it was identified that ML inhibited two mRNA—MMP-9
and IL-8—and the protein expression in TPA-treated MCF-7 cells. Moreover, the mechanism
of inhibition of MA on MCF-7 cells was followed by the targeting of the TPA-stimulated
phosphorylation of ERK and the downstream factors, AP-1 and STAT3.
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5.2.4. Antroquinonol
Antroquinonol (Figure 4) extracted from the mycelium of Antrodia camphorate, was
identified as the smallest anticancer molecule [196]. Although the mechanism of action
of Antroquinonol remains unclear, some evidence suggested that antroquinonol inhibits
RAS- and RAS-mediated protein function by blocking the expression of isopropyl protein
transferase. Moreover, it was identified that antroquinonol selectively binds with FPTase
and geranyl transferase 1, the most RAS-activating enzyme. Antroquinonol effectively
inhibits the RAS activity in vitro. It was also determined that antroquinonol can induce
apoptosis by blocking the PI3K/mTOR pathway [197]. Moreover, antroquinonol treatment
in lung cancer cells induces autophagic property of LC3B-1 to LC3B-II.
5.2.5. 5-CQA (5-O-Caffeoylquinic Acid)
Chlorogenic acid (5-O-caffeoylquinic acid, 5-CQA) was identified in coffee beans used
to make green coffee and, after roasting, black coffee, a widespread drink worldwide. 5CQA
(Figure 4) was the first natural compound targeting RAS mutation [198]. A current study
found that intake of healthy food, abundant in polyphenols, decreases neurovegetative diseases, with 5-CQA being one of them [199]. Moreover, 5CQA affects inflammation, cancer,
and neurovegetative diseases. Although the molecular mechanism of biological effectiveness of 5CQA is not investigated, an investigation found that it inhibits RAS-dependent
breast cancer. After evaluating the standard NMR result, it was identified that 5-CQA
reduces cancer growth by modulating p42/p44 MAPKs activation/phosphorylation. A
molecular docking study found four binding sites (S-I-P and S-II-P for both complexes, and
S-I-II-P for the HRASGDP complex only) in oncogenic HRAS protein where 5-CQA can
bind and determined the FullFitness scores. It was also identified that 5-CQA noncompetitively interacted with the binding site because the computationally found 5-CQA binding
site was distinct from the active site.
5.2.6. Lupeol
Lupeol (Figure 4) is a triterpenoid, a FPTase inhibitor, and specifically inhibits KRAS
mutants, but not wt KRAS [200]. After analyzing its crystal structure, Ganaie et al. identified
20 terpenoids for their KRAS-binding affinity. In a comprehensive study on lup-20 (29)- en3b-ol (lupeol) as a KRAS inhibitor, differential scanning fluorimetry, immunoprecipitation
assays, isothermal titration calorimetry were performed, and lupeol was identified as
a potent KRAS inhibitor. Lupeol has a potential inhibitory effect on mutant KRASG12V .
In vivo lupeol administration in a mouse model showed inhibition of the development of
pancreatic intraepithelial neoplasia.
5.2.7. Grifolin and Neogrifolin
Grifolin (7a) and neogrifolin (7b) (Figure 4) were isolated from the ethanolic extract of
a bioactive mushroom that is indigenous to British Columbia [186]. One more compound,
confluentin, was isolated. We discussed the biological activity of confluentin in an earlier
section. The aforementioned investigation showed that grifolin and neogrifolin could
inhibit oncogenic KRAS in human colon cancer. They also exerted their inhibitory effect in
the presence of wild KRAS [186].
5.3. Natural Product RAS Inhibitor with Acyclic Skeleton
Chaethomellic Acids A
Chaethomellic acids are a class of alkyl dicarboxylic acids isolated from Chaetomella
acutiseta [201]. An investigation identified two novel compounds, chaethomellic acid A
(Figure 5) and B, identified three structural types of FPTase inhibitors—phosphonic acids,
chaethomellic acids, and zaragozic acids—that produced weak inhibition to geranyl protein
transferase, but each of them showed competitive effects towards farnesyl diphosphate
when inhibiting FPTase. Among these three classes, phosphonic acid and chaethomellic
acid showed outstanding selectivity towards FPTase and geranyl transferase activity, while
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zaragozic acids showed less selectivity. Mechanistically, chaethomellic acid A competitively inhibits FPTase and noncompetitively inhibits RAS protein. To identify the FPTase
activity, all the compounds were assayed in Ha-RAS containing NIH3T3 fibroblast cells;
chaethomellic acids and zaragozic acids had no effect in this assay.

Figure 5. Acyclic natural product RAS inhibitor Chaetomellic acid A.

Nogueira et al. [202] identified that long-term treatment with chaethomellic acid A
reduces renal mass reduction-induced renal fibrosis in a rat model by selectively inhibiting
Ha-Ras farnesylation. After analyzing the previous studies [203,204], it was hypothesized
that chaethomellic acid A treated CKD by altering the Raf/MEK/ERK and PI3K-Akt
pathways. Chaethomellic acid A was administered in three different rat models (23 µg/Kg),
three times a week for 6 months, resulting in significantly decreased renal fibrosis, mainly
glomerulosclerosis and arteriolosclerosis.
6. Conclusions
Up- and down-regulations of proteins are crucial in terms of causing diseases, including cancer. RAS family proteins, particularly KRAS, play central roles in different
stages of cancer development, invasion, propagation, metathesis, and angiogenesis, leading
to the formation of solid tumors [205–207]. Previously, there was a myth that KRAS is
undruggable, but continuous efforts from different parts of the world have established that
it is druggable. Despite the progress, the current protocols encounter several limitations,
including the loss of selectivity, the causing of toxicity, and the production of incongruent
patient outcomes. Various genomic and histologic mechanisms promote resistance to covalent KRASG12C inhibitors. For example, the development of heterogeneous responses to
some KRAS inhibitors, such as MRTX849 or AMG510, bypass their anti-growth effects by
producing more KRAS variants, to which these inhibitors do not bind. The developed KRAS
alterations include G12D/R/V/W, G13D, Q61H, R68S, H95D/Q/R, Y96C, and high-level
amplification of the KRASG12C allele. The attained bypass mechanisms of resistance include
MET amplification, activating mutations in NRAS, BRAF, MAP2K1, and RET, oncogenic
fusions involving ALK, RET, BRAF, RAF1, and FGFR3, and loss-of-function mutations in
NF1 and PTEN. Accordingly, more in-depth research is required to overcome the resistance
towards KRAS inhibitors. In conclusion, in spite of there being unceasing progress, many
miles remain in the development of RAS inhibitors with higher potency and selectivity,
lower toxicity, and apprehended drug-resistance.
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